Radium-223 (Xofigo®) is indicated for the treatment of adults with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. It is for use in the hospital setting.
|28/11/2013||23/12/2013||Full Pharmacoeconomic Evaluation Recommended.|
|11/04/2014||12/12/2014||Reimbursement Not Recommended|
The NCPE does not recommend reimbursement of radium-223 at the submitted price .
The HSE has approved reimbursement following confidential price negotiations.